Genvor Incorporated · OTC:GNVR
Genvor — Investor Presentation (March 2026)
18 slides from Genvor's investor presentation, March 2026
Slide 1: Peptides by Design: Corporate Overview & Investor Presentation
OTCQB: GNVR Peptides by Design TM March 2026 Corporate Overview & Investor Presentation
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains "forward-looking statements." The statements contained in this presentation that are not purely historical are forward-looking statements. Forward-looking statements give the Company's current expectations or forecasts of future events. Such stat
Slide 3: Genvor is on a Mission to Transform Agriculture and Human Health & Wellness
Genvor is on a Mission to Transform Agriculture and Human Health & Wellness Through its AI-Accelerated Peptide Platform The Founders’ Vision Dr. Jesse Jaynes and Dr. Clayton Yates, leading experts in therapeutic and agricultural peptides, had a bold vision: If peptides could revolutionize human medi
Slide 4: Agriculture Faces a $220 Billion Crisis
Agriculture Faces a $220 Billion Crisis There’s a significant opportunity to leverage peptides to defend against devastating plant pathogens while optimizing agricultural performance. Food production must double by 2050 to meet the food demand of the global population growth to 9.6 billion people1.
Slide 5: The Agricultural Biologicals Market is Growing Rapidly with Regulatory Tailwinds
The Agricultural Biologicals Market is Growing Rapidly with Regulatory Tailwinds Traditional Ag chemical growth is peaking and faces regulatory headwinds, while Biochemicals are in the beginning stages of a generational breakout. Peptide Regulatory Advantage Agricultural Biologicals Market1 ($ Billi
Slide 6: Consumer Peptide Market is Experiencing Strong Growth with Favorable Regulatory Pathways
Consumer Peptide Market is Experiencing Strong Growth with Favorable Regulatory Pathways Rising consumer demand for science-backed recovery, performance, and wellness solutions is driving rapid expansion of the global peptide supplements market. OTC Regulatory Advantage Global Peptide Supplements Ma
Slide 7: Genvor Corporate Overview
Genvor Corporate Overview Genvor is a biotechnology company harnessing AI to generate novel peptides that deliver high- performance solutions across agriculture and human health Key Value Drivers Strategic Adoption Model Competitive Advantages Market Opportunity ✓ AI-Accelerated platform ✓ Scalabili
Slide 8: Peptides Designed for a Variety of Delivery Modes Across Agriculture and Human Health
Genvor’s Peptides are Designed for a Variety of Delivery Modes Across Agriculture and Human Health Biological Sprays Seed Traits OTC Delivery Used for greenhouse and specialty crops like Peptides encoded directly into seeds of Peptides formulated for nasal berries, herbs, and vegetables. large-scale
Slide 9: Genvor's Competitive Advantage: The BioCypher Platform
Genvor’s Competitive Advantage:The BioCypher Platform Genvor’s digitized peptide library of millions of peptides represents a breakthrough opportunity to efficiently generate peptides across agriculture and human health faster than anyone else Proprietary Research Foundation Unmatched Library Scale
Slide 10: Our Four Core Peptide Technologies
Our Four Core Peptide Technologies At the heart of our innovation are four proprietary peptide classes that we engineer for high-impact applications in plant health, animal feed, and sustainable agriculture. Antimicrobial Peptides C-terminally Encoded Nutrient Enhancing Insecticidal Peptides (AMPs)
Slide 11: Genvor Peptide Development Pipeline
Genvor Peptide Development Pipeline Three AMP Families & One NEP Family in Active Development Potential Strategic Partners Typically Begin to Express Interest in Transactions During These Stages Trait Regulatory Crop Peptide Family R&D Trait Development Testing Validation Approval Citrus Anti-Pathog
Slide 12: Lead Peptides Demonstrate Broad-Spectrum Efficacy Against Major Agricultural Pathogens
Lead Peptides Demonstrate Broad-Spectrum Efficacy Against Major Agricultural Pathogens Genvor’s synthetic peptide candidates demonstrated strong antifungal activity at low concentrations, de-risking the program for partnerships and commercial advancement Design Generation 3rd 2nd 1st Synthetic Pepti
Slide 13: Proprietary Formulations Achieve Commercial-Grade Peptide Stability
Genvor’s Proprietary Formulations Achieve Commercial-Grade Peptide Stability Advanced formulation technology solves industry-wide peptide stability challenges, enabling 2+ year shelf life required for commercial agricultural markets Genvor’s Formulations are Market GV185 GV197 Ready: 100 96 100 98 9
Slide 14: Third-Party Validation: Powering Progress Together
Third-Party Validation: Powering Progress Together World-class partnerships accelerate technology development and de-risk commercialization BAYER GOLDEN TICKET USDA CRADA TUSKEGEE UNIVERSITY Inaugural Recipient - 2024 7+ year collaboration Teaming Agreement - 2025 First company selected for Exclusiv
Slide 15: Dual-Market Business Model Creates Multiple Revenue Pathways
Dual-Market Business Model Creates Multiple Revenue Pathways from a Single Platform Genvor’s BioCypher platform powers two commercialization strategies: a licensing-first model in agriculture and a direct-to-consumer model in human health and wellness BioCypher Platform — One Technology Core AGRICUL
Slide 16: Proven Performance And IP Protection Validate Commercial Potential
Proven Performance And IP Protection Validate Commercial Potential Patent Portfolio Strength First U.S. patent issued in 2015 covering eight peptides, including all key pipeline peptides. Transgenic Protection Secured Second U.S. patent issued in 2021 for transgenic corn with anti-fungal peptide AGM
Slide 17: Experienced Team Brings Deep Industry Expertise
Experienced Team Brings Deep Industry Expertise Agribusiness Leadership Scientific Innovation Scientific Innovation Biologicals Leadership Jesse Jaynes, Ph.D. George Stavrides, Ph.D. Chad Pawlak Sr., MBA Clayton C. Yates, Ph.D. Co-Founder, Chairman & Director of EVP, Business Development & Chief Exe
Slide 18: genvor.com
genvor genvor.com